Gilead and LEO Pharma
Type: Licensing agreement
In-Licensee: Gilead Sciences
Out-Licensor: LEO Pharma
Focus: Gilead (Oral STAT6 programs), LEO Pharma (Topical STAT6 product)
Upfront Payment: $250 million
Total Potential Payment: Up to $1.7 billion
Royalties Received: High single digits to the mid-teens
Financial Impact: $0.15 to $0.17 decrease in GAAP and non-GAAP 2025 EPS
Gilead Sciences, Inc. and LEO Pharma have entered a licensing agreement to accelerate the development and commercialization of LEO Pharma’s small-molecule oral STAT6 (signal transducer and activator of transcription 6) programs, which target inflammatory diseases. Under the agreement, LEO Pharma will receive up to $1.7 billion in total payments, including an upfront payment of $250 million. Additionally, LEO Pharma may earn tiered royalties on sales of oral STAT6 products, ranging from the high single digits to the mid-teens. Gilead, in turn, may receive tiered royalties on sales of topical STAT6 products, ranging from the high single digits to the mid-teens. Gilead will include acquired IPR&D expenses in its non-generally accepted accounting principles financial measures. This transaction is expected to lower Gilead’s generally accepted accounting principles (GAAP) and non-generally accepted accounting principles (non-GAAP) 2025 EPS by approximately $0.15 to $0.17.
STAT6
STAT6 is a transcription factor that plays a crucial role in regulating immune responses and is also associated with cancer. Research and diagnostic tools targeting STAT6 include antibodies, ELISA kits, recombinant proteins, and cDNA clones, which are widely utilized in laboratory studies and clinical investigations.
STAT6: Dual role in Inflammation
STAT6 has a dual function in inflammation, serving as both a promoter and a suppressor of inflammatory responses. While it is a central regulator of type 2 (T2) inflammation, studies have also shown that STAT6 can suppress pro-inflammatory enhancer activity and restrain macrophage activation, contributing to anti-inflammatory effects. Its role is highly context-dependent, varying based on cell type and the presence of other signalling pathways.
Five years' market revenue of anti-inflammatory drugs
The global market for anti-inflammatory drugs has experienced consistent growth over the past five years and continues to expand significantly. Valued at $120.46 billion in 2023, it is projected to reach $272.35 billion by 2033, reflecting a compound annual growth rate (CAGR) of 8.5%. This growth is fueled by rising awareness of inflammatory diseases and ongoing advancements in treatment options.
Five years market revenue of anti-inflammatory drugs (2020-2024)
Fig 4: Market revenue of anti-inflammatory drugs
Market Impact of This Partnership
Gilead, traditionally known for its HIV treatments, is expanding into areas such as inflammation, oncology, and others. LEO Pharma, with a strong expertise in dermatology and inflammatory diseases, is well-positioned as a partner for the development of the STAT6 program. The collaboration between Gilead and LEO Pharma is anticipated to reduce Gilead’s 2025 earnings by approximately $0.15–$0.17 per share, mainly due to an upfront payment of $250 million and potential total payments reaching up to $1.7 billion, including milestone bonuses. Under the agreement, Gilead secures exclusive global rights to develop and commercialize oral STAT6 therapies for inflammatory diseases, while LEO Pharma will have the option to potentially co-commercialize oral programs for dermatology outside the United States. LEO Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Despite the short-term financial impact, Gilead likely pursued the partnership to access the promising preclinical STAT6 program and enhance its research capabilities in the inflammation field.
“The Gilead–LEO Pharma collaboration is expected to be dilutive to 2025 EPS by $0.15–$0.17.”